HACKENSACK, N.J - August 18, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a collaboration with The Addario Lung Cancer Medical Institute “ALCMI” to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions’ TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers. Champions’ global infrastructure will be leveraged to support this multi-year program.
Mark Weinstein
Recent Posts
Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models
Aug 18, 2017 8:30:53 AM / by Mark Weinstein
Champions Oncology Reports 38% Revenue Growth
Jul 28, 2017 12:06:25 PM / by Mark Weinstein
Hackensack, NJ – July 27, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth quarter and year ended April 30, 2017.
Champions Oncology Reports 40% Revenue Growth
Mar 16, 2017 4:16:28 PM / by Mark Weinstein
Hackensack, NJ – March 16, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third quarter ended January 31, 2017.
Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland
Mar 16, 2017 9:10:23 AM / by Mark Weinstein
HACKENSACK, NJ - March 16, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced plans for opening a new lab facility in Rockville, Maryland during the second quarter of its 2018 fiscal year. At current levels of business, the Company expects to realize a 10% reduction in lab costs.
Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research
Feb 16, 2017 9:50:08 AM / by Mark Weinstein
Expands Champions’ product line in unique PDX models
HACKENSACK, NJ - February 16, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the addition of new cohorts of PDX models to their existing TumorBank.
